Synergism between the metabolic syndrome components and cancer incidence: results from a prospective nested case–control study based on the China Health and Retirement Longitudinal Study (CHARLS). Issue 9 (17th September 2022)

• Record Type: Journal Article
• Authors: Li, Lin; Meng, Fang; Xu, Dongkui; Xu, Lingkai; Qiu, Junlan; Shu, Xiaochen
• Is Part Of: BMJ open. Volume 12:Issue 9(2022)
• Publication Date: 2022-09-17
• Subjects: EPIDEMIOLOGY -- ONCOLOGY -- Epidemiology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2022-061362
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: Synergism between the metabolic syndrome (MetSyn) components and cancer incidence still remains inconclusive. We aimed to investigate the unique or joint role of MetSyn components in cancer onset. Design: We conducted a prospective nested case–control study based on the China Health and Retirement Longitudinal Study. Setting: An ongoing national representative longitudinal study included follow-up survey of people aged 45 years and older and their partners living in private households in China. Participants: There were 17 708 individuals included at baseline. A total of 306 incident cancers was identified during the follow-up. For every case, we used incidence-density sampling to match three concurrent cancer-free controls by age, sex, and both duration and calendar time of follow-up. Exposure of interest was any MetSyn diagnosis at baseline. Results: We observed elevation in cancer risk associated with MetSyn in a significant way when the number of MetSyn components was over three (OR: 1.88; 95% CI: 1.19 to 2.97), or when components contained any of elevated triglycerides (OR: 1.61; 95% CI: 1.05 to 2.48), reduced high-density lipoprotein (HDL) cholesterol (OR: 2.33; 95% CI: 1.40 to 3.86) or elevated blood pressure (OR: 1.65; 95% CI: 1.04 to 2.59) after consistent multiple adjustments in different models. The highest cancer risk was in the female reproductive system and breast cancer (OR: 4.22; 95% CI: 1.62 to 10.95) followed by digestive system (OR: 1.67; 95% CI: 1.11 to 2.53). Sensitivity analyses showed similar results after first follow-up was excluded. However, any unique MetSyn component was not associated with increased cancer risk. Interestingly, the reduced HDL was observed to be widely associated with over twofold increased risk of cancer, only when together with other MetSyn components. Conclusion: MetSyn components, in a collaborative manner rather than its unique component, were associated with elevated cancer risk. Not only obesity but even subtle metabolic disturbances may give rise to cancer.